Immunoscore As Decision Guidance for Adjuvant Chemotherapy in Colon Cancer

Exclusion Criteria

• •Neoadjuvant treatment
• •Metastatic disease
• •Pregnancy, breastfeeding or expectancy to conceive
• •Disagreement of participants with reproductive potential to use contraception throughout the study period and for up to 180 days after the last dose of study therapy
• •Uncontrolled or significant cardiovascular disease (myocardial infarction, uncontrolled angina, any history of clinically significant arrhythmias, QTc prolongation in males \> 450 ms and \> 470 ms in females, participants with history of myocarditis)
• •Hepatitis B or C
• •Human immunodeficiency virus (HIV)
• •Immunodeficiency
• •Allogeneic tissue or solid organ transplantation
• •Systemic steroids or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment
• •Diagnosed and/or treated additional malignancy within 5 years of randomization, with the exception of curatively-treated basal cell or squamous cell carcinoma of the skin and/or curatively-resected in situ cervical and/or breast cancers
• •Participants with serious or uncontrolled medical disorders
• •Allergies and adverse drug reaction (history of allergy or hypersensitivity to study drug components, contraindications to any of the study drugs of the chemotherapy regimen)